CA3130154A1 - Pyrazolopyridine derivatives as inhibitors of pask - Google Patents

Pyrazolopyridine derivatives as inhibitors of pask Download PDF

Info

Publication number
CA3130154A1
CA3130154A1 CA3130154A CA3130154A CA3130154A1 CA 3130154 A1 CA3130154 A1 CA 3130154A1 CA 3130154 A CA3130154 A CA 3130154A CA 3130154 A CA3130154 A CA 3130154A CA 3130154 A1 CA3130154 A1 CA 3130154A1
Authority
CA
Canada
Prior art keywords
compound
pyrazolo
int
carboxylate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3130154A
Other languages
English (en)
French (fr)
Inventor
Stephane Nicolas Alain Beaumont
Xavier Marie Bock
Daniel COMAS MARTINEZ
Agnes Marie Joncour
Frederic Gilbert Labeguere
Miriam Lopez Ramos
Taoues Temal-Laib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CA3130154A1 publication Critical patent/CA3130154A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3130154A 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask Pending CA3130154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (1)

Publication Number Publication Date
CA3130154A1 true CA3130154A1 (en) 2020-09-03

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3130154A Pending CA3130154A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US10392389B2 (en) * 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
EP3615538B1 (en) * 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Also Published As

Publication number Publication date
TW202045505A (zh) 2020-12-16
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
ES2963409T3 (es) 2024-03-27
MX2021010093A (es) 2021-09-21
BR112021016642A2 (pt) 2021-11-03
KR20210134001A (ko) 2021-11-08
IL285751A (en) 2021-10-31
US20220144823A1 (en) 2022-05-12
PH12021552032A1 (en) 2022-11-14
AU2020229041A1 (en) 2021-10-21
WO2020173739A1 (en) 2020-09-03
EP3931191A1 (en) 2022-01-05
GB201902490D0 (en) 2019-04-10
CN113474344A (zh) 2021-10-01
JP2022525121A (ja) 2022-05-11
EP3931191B1 (en) 2023-10-04
CO2021010485A2 (es) 2021-08-19
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
AU2012357067B2 (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
AU2014240388B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
AU2014315109B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
AU2013254307B2 (en) Cyclic bridgehead ether DGAT1 inhibitors
AU2018271876B2 (en) Pyrazole MAGL inhibitors
CA2791672A1 (en) Positive allosteric modulators of mglur2
PH12015502055B1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014095798A1 (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
WO2018052772A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
CA3130154A1 (en) Pyrazolopyridine derivatives as inhibitors of pask
WO2025133915A1 (en) Compounds which bind to pnpla3i148m and their use to treat liver diseases
HK1201528B (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331